Bing Liu

Hunan University — China

Medicine · Health Sciences

21h-index1.5kcitations80works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(52), Cancer, Hypoxia, and Metabolism(17), Protein Degradation and Inhibitors(9), Ubiquitin and proteasome pathways(7), Virus-based gene therapy research(6)

Publications80 total

Supplementary Figure S6 G-K from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Data from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Information from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Table S1 from Network Modeling of microRNA–mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN
2023Open Access
Supplementary Figure S4 A-E from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S5 F-H from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S1 A-E from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S3 A-E from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S3 A-E from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S5 A-E from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Data from Network Modeling of microRNA–mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN
2023Open Access
Supplementary Figure S5 F-H from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure Legends from A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers
2023Open Access
Figure S1-S6 from Network Modeling of microRNA–mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN
2023Open Access
Supplementary Figure S2A-C from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S3 F-G from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Data from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Figure S5 A-E from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
Supplementary Table S1 from Network Modeling of microRNA–mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN
2023Open Access
Supplementary Figure S1 F-I from Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Murray D. Norris(41), Michelle Haber(41), Tao Liu(33), Glenn M. Marshall(31), Belamy B. Cheung(29), Jamie I. Fletcher(24), Giovanni Perini(24), Daniel R. Carter(23), Jayne Murray(22), Chelsea Mayoh(22), Jessica Koach(18), Giorgio Milazzo(17), André Oberthuer(17), Andrew J. Gifford(15), Jessica L. Bell(14), Stefan Hüttelmaier(14), Joshua A. McCarroll(14), Jessica K. Holien(13), Hassina Massudi(13), Olivia C. Ciampa(13)